| Combination antiretroviral therapy and the risk of myocardial infarction Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group New England Journal of Medicine 349 (21), 1993-2003, 2003 | 2131 | 2003 |
| Monkeypox virus infection in humans across 16 countries—April–June 2022 JP Thornhill, S Barkati, S Walmsley, J Rockstroh, A Antinori, LB Harrison, ... New England Journal of Medicine 387 (8), 679-691, 2022 | 1914 | 2022 |
| Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study Data Collection on Adverse Events of Anti-HIV Drugs Study Group Archives of internal medicine 166 (15), 1632-1641, 2006 | 1515 | 2006 |
| Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration D: A: D Study Group The Lancet 371 (9622), 1417-1426, 2008 | 1188 | 2008 |
| Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of … AJ Rodger, V Cambiano, T Bruun, P Vernazza, S Collins, O Degen, ... The Lancet 393 (10189), 2428-2438, 2019 | 1147 | 2019 |
| Tocilizumab in patients with severe COVID-19: a retrospective cohort study G Guaraldi, M Meschiari, A Cozzi-Lepri, J Milic, R Tonelli, M Menozzi, ... The Lancet Rheumatology 2 (8), e474-e484, 2020 | 1078 | 2020 |
| Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia S De Biasi, M Meschiari, L Gibellini, C Bellinazzi, R Borella, L Fidanza, ... Nature communications 11 (1), 3434, 2020 | 809 | 2020 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 805 | 2021 |
| Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study G Ferrara, M Losi, R D'Amico, P Roversi, R Piro, M Meacci, B Meccugni, ... The Lancet 367 (9519), 1328-1334, 2006 | 724 | 2006 |
| Common genetic variation and the control of HIV-1 in humans J Fellay, D Ge, KV Shianna, S Colombo, B Ledergerber, ET Cirulli, ... PLoS genetics 5 (12), e1000791, 2009 | 480 | 2009 |
| Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study N Friis-Møller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ... European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010 | 461 | 2010 |
| Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 … P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ... The Lancet 393 (10167), 143-155, 2019 | 433 | 2019 |
| Long-term consequences of COVID-19: research needs D Yelin, E Wirtheim, P Vetter, AC Kalil, J Bruchfeld, M Runold, G Guaraldi, ... The Lancet Infectious Diseases 20 (10), 1115-1117, 2020 | 413 | 2020 |
| Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes B Ledergerber The Lancet 364 (9428), 51-62, 2004 | 392 | 2004 |
| Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial D Yahav, E Franceschini, F Koppel, A Turjeman, T Babich, R Bitterman, ... Clinical Infectious Diseases 69 (7), 1091-1098, 2019 | 388 | 2019 |
| Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease G Monti, M Galli, F Invernizzi, P Pioltelli, F Saccardo, A Monteverde, ... QJM: An International Journal of Medicine 88 (2), 115-126, 1995 | 383 | 1995 |
| Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase–producing K. pneumoniae M Tumbarello, EM Trecarichi, A Corona, FG De Rosa, M Bassetti, ... Clinical Infectious Diseases 68 (3), 355-364, 2019 | 380 | 2019 |
| Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease L Marthey, C Mateus, C Mussini, M Nachury, S Nancey, F Grange, ... Journal of Crohn's and Colitis 10 (4), 395-401, 2016 | 351 | 2016 |
| CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study C Mussini, P Lorenzini, A Cozzi-Lepri, G Lapadula, G Marchetti, E Nicastri, ... The lancet HIV 2 (3), e98-e106, 2015 | 330 | 2015 |
| All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort … Collaboration of Observational HIV Epidemiological Research Europe (COHERE ... International journal of epidemiology 41 (2), 433-445, 2012 | 321 | 2012 |
